The European Commission has approved RINVOQ (upadacitinib) for treating severe alopecia areata in adults and adolescents 12 years and older, based on Phase 3 clinical trials demonstrating significant scalp hair regrowth and improvements in eyebrows and eyelashes after 24 weeks. This marks RINVOQ as the first JAK inhibitor to achieve complete scalp hair regrowth compared to placebo. The approval offers a new treatment option for patients facing the physical and psychological burdens of this autoimmune disease. AbbVie continues to study RINVOQ for other immune-mediated conditions and is seeking FDA approval for alopecia areata in the U.S.
Investing in three blue-chip dividend stocks—Altria, AbbVie, and Chevron—each paying dividends quarterly on different schedules, can create a monthly income stream throughout the year. Altria pays in January, April, July, and October with a high yiel...
With inflation expected to remain high, five Dividend Aristocrats—companies with 25+ years of rising dividends—are recommended for investors seeking stable income and growth. These firms, including AbbVie, Chevron, PepsiCo, Procter & Gamble, and Targ...
AbbVie has submitted an application to the European Medicines Agency (EMA) for approval of SKYRIZI (risankizumab) as a subcutaneous induction treatment for adults with moderately to severely active Crohn's disease. This follows positive results from ...
AbbVie continues to demonstrate solid revenue and earnings growth driven by the strong performance of Skyrizi and Rinvoq, which compensate for declines in Humira sales. Recent regulatory approvals and expanded market opportunities support the company...
